<DOC>
	<DOCNO>NCT00981617</DOCNO>
	<brief_summary>This study evaluate safety efficacy ALKS33 ( RDC-0313 ) compare placebo adult alcohol dependence . There 11 study visit conduct period 4 month . The study period include screen visit , 12-week treatment period , follow-up visit .</brief_summary>
	<brief_title>ALK33-005 : A Study ALKS33 ( RDC-0313 ) Adults With Alcohol Dependence</brief_title>
	<detailed_description>This multi-center , randomize , double-blind , placebo-controlled study . A 3-stage adaptive design use . Following screening , eligible subject randomize equally 1 4 group ( ALKS33 [ RDC-0313 ] [ 1 , 2.5 , OR 10 mg ] , match placebo ) .</detailed_description>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>ALKS-33</mesh_term>
	<criteria>18 year age old Current diagnosis alcohol dependence , recent heavy drinking ( eg , 5 drink per day men 4 drink per day woman ) A noncustodial stable residence telephone Women reproductive potential must agree use approve method contraception duration study Ability stop drinking prior receive study drug Pregnancy and/or current breastfeed Past present history AIDSindicator disease Current dependence drug ( exclusive nicotine , caffeine , alcohol ) Positive urine drug screen benzodiazepine ( unless use shortterm basis alcohol detoxification ) , opioids , amphetamines/ methamphetamine cocaine Visits 1 2 Clinically significant medical condition Current anticipate need prescribe opioid medication study period Use naltrexone within 60 day prior screen Current need antidepressant ( within 30 day prior entry ) Participation clinical trial pharmacological agent within 30 day prior screen Parole probation pending legal proceeding potential incarceration study period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>